Perspective Therapeutics reports Q2 EPS (29c), consensus (29c)

Reports Q2 revenue $300,000, consensus $170,370. Cash, cash equivalents, and short-term investments as of June 30 were approximately $192M as compared to $227M as of December 31, 2024. “The recent and upcoming scientific data presentations from our clinical programs reflect our companywide commitment to helping cancer patients facing limited treatment options in their disease journey,” said Thijs Spoor, Perspective’s CEO. “These clinical data disclosures are enabled by strong participation in our clinical trials and stable supply of all three clinical-stage, proprietary potential new medicines based on our next generation targeted radiopharmaceutical technology platform. We are committed to submitting further updates as appropriate at upcoming scientific forums on patients who have received treatments with our potential new medicines through mid-2026 and beyond.”